A guide to plasma membrane solute carrier proteins

MD Pizzagalli, A Bensimon… - The FEBS …, 2021 - Wiley Online Library
This review aims to serve as an introduction to the solute carrier proteins (SLC) superfamily
of transporter proteins and their roles in human cells. The SLC superfamily currently …

[HTML][HTML] Glucose transporters as a target for anticancer therapy

M Pliszka, L Szablewski - Cancers, 2021 - mdpi.com
Simple Summary For mammalian cells, glucose is a major source of energy. In the presence
of oxygen, a complete breakdown of glucose generates 36 molecules of ATP from one …

[HTML][HTML] SGLT-2 inhibitors in cancer treatment—mechanisms of action and emerging new perspectives

M Dutka, R Bobiński, T Francuz, W Garczorz, K Zimmer… - Cancers, 2022 - mdpi.com
Simple Summary Despite significant advances in the treatment of cancer, it remains a major
cause of death worldwide and new treatment options are constantly being sought. An …

Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review

N Shakour, S Karami, M Iranshahi, AE Butler… - Diabetes & Metabolic …, 2023 - Elsevier
Background and aims Scar tissue accumulation in organs is the underlying cause of many
fibrotic diseases. Due to the extensive array of organs affected, the long-term nature of …

[HTML][HTML] Cell line-directed breast cancer research based on glucose metabolism status

P Farhadi, R Yarani, E Valipour, S Kiani… - Biomedicine & …, 2022 - Elsevier
Metabolic reprogramming is a potential hallmark of tumor cells to support continuous
proliferation. Metabolic heterogeneity in breast cancer patients has been highlighted as the …

[HTML][HTML] Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization

X Niu, J Ma, J Li, Y Gu, L Yin, Y Wang, X Zhou… - Cell death & …, 2021 - nature.com
Endocrine therapy is the standard treatment for estrogen receptor (ER)-positive breast
cancer, but tumors eventually develop resistance. However, endocrine therapy resistance …

pH-redox responsive cascade-targeted liposomes to intelligently deliver doxorubicin prodrugs and lonidamine for glioma

Y Zhao, Y Peng, Z Yang, J Lu, R Li, Y Shi, Y Du… - European Journal of …, 2022 - Elsevier
To synergistically treat glioma with a combination chemotherapy, we design and prepare
novel cascade-targeted liposomes (Lip-TPGS) using glucose and triphenylphosphonium …

Glucose and triphenylphosphonium co-modified redox-sensitive liposomes to synergistically treat glioma with doxorubicin and lonidamine

Y Peng, J Lu, R Li, Y Zhao, L Hai, L Guo… - ACS Applied Materials …, 2021 - ACS Publications
Glioma is one of the most lethal and complex tumors, and thus, an effective drug delivery
system must selectively target the tumor sites and release its cargos in a controlled manner …

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment–a review

KTK Lau, L Ng, JWH Wong, HHF Loong… - Reviews in Endocrine …, 2021 - Springer
Developed as an antidiabetic drug, recent evidence suggests that several sodium-glucose
co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit …

[HTML][HTML] Diabetes, antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors

M Dąbrowski - International Journal of Molecular Sciences, 2021 - mdpi.com
In the last decade, cancer became the leading cause of death in the population under 65 in
the European Union. Diabetes is also considered as a factor increasing risk of cancer …